Key Drivers
- Quarterly profitability
- Large annual charges
- Strong cash position
AIAI Summary
HNGE has visibly shifted from growth-at-all-costs to quarter-level profitability and positive FCF—transforming into a subscription-like MSK business with real near-term cash-generation optionality—but investors should demand multi-quarter operating profit, transparent disclosure of the FY one-time charges, and sustained win-rate/contract momentum (or treat a break below $38–41 as a signal to re-price execution risk).
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Quarterly profitability
- •Large annual charges
- •Strong cash position
HNGE showed a profitable quarter with strong margins and positive free cash flow but deep FY operating losses driven by outsized R&D/SG&A and a large cumulative deficit that undermine its balance sheet and valuation.
Price Behavior
Key Price Behavior Insights:
- •Modest net gain
- •Weakening momentum
- •Elevated volatility
Over the last month HNGE is modestly up (~+6.7%) but momentum has weakened after a pullback from $46.14 to $42.48, leaving resistance near $45.90–$49.40 and support at $38.45–$41.00 amid elevated short‑term volatility.
Pullback from $46.14 on 2026-03-06 to $42.48 on 2026-03-20 highlights short-term selling pressure
Sentiment & News
Key News Insights:
- •Analyst upside
- •Post-earnings gain
- •Data/AI moat
Analysts see roughly 26% upside and shares have climbed post-earnings as Hinge Health highlights its patient movement data/AI edge and adds a seasoned operator to the board to scale operations.
The combination of upward analyst revisions, recent share strength, proprietary data emphasis and a strategic board hire should support investor confidence and positioning for growth execution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings